Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Raises $8.8M in Financing

NEW YORK (GenomeWeb News) – Response Genetics has raised $8.8 million through a private placement of its stock with GlaxoSmithKline and an existing "significant" stockholder, the firm said today.

The Los Angeles-based molecular diagnostics firm placed 8 million newly issued shares of its common stock at a price of $1.10 per share. The placement closed today.

"We are pleased to welcome GlaxoSmithKline as a new investor, given our long-standing relationship," Thomas Bologna, chairman and CEO of Response Genetics, said in a statement. "The capital raised will help support our continued efforts in building a sustainable business of high value genetic tests for cancer patients as well as a premier pharmaceutical services business."

Response Genetics inked a deal with GlaxoSmithKline in 2010, under which it licensed to the drug giant non-exclusive rights to its PCR technology and agreed to provide diagnostic expertise to assess BRAF gene mutations in human tumor samples. The firm also has provided GSK with genetic testing services to support its drug development programs.

In Thursday morning trade on the Nasdaq, shares of Response Genetics were up 47 percent at $1.33.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.